Therefore, if the levels of serum IL-33 are also correlated with pathogenic degrees of the liver in CHC patients, the levels of serum IL-33 may be used as a new biomarker for the diagnosis of liver damages in CHC patients. The gene discussed is IL33; the disease is cryohydrocytosis.